An open-label, 2-way crossover study of steady-state intragastric pH control comparing 2 dosage regimens of esomeprazole and lansoprazole in Barrett's esophagus patients

Trial Profile

An open-label, 2-way crossover study of steady-state intragastric pH control comparing 2 dosage regimens of esomeprazole and lansoprazole in Barrett's esophagus patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2009

At a glance

  • Drugs Esomeprazole; Lansoprazole
  • Indications Barrett's oesophagus; Gastro-oesophageal reflux
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Jul 2009 Results have been reported in Alimentary Pharmacology and Therapeutics.
    • 19 Jun 2007 Status changed from in progress to completed.
    • 14 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top